8.37

1.09% 0.09

After Hours: 8.37

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $8.37, with a volume of 1.88M. It is up +1.09% in the last 24 hours and up +35.44% over the past month. Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Previous Close:

$8.28

Open:

$8.2

24h Volume:

1.88M

Relative Volume:

1.08

Market Cap:

$1.45B

Revenue:

$314.85M

Net Income/Loss:

$12.01M

P/E Ratio:

127.79

EPS:

0.0655

Net Cash Flow:

$47.52M

1W Performance:

+8.14%

1M Performance:

+35.44%

6M Performance:

+20.26%

1Y Performance:

+76.21%

1-Day Range:

$8.20

$8.50

1-Week Range:

$7.735

$8.50

52-Week Range:

$4.62

$10.08

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

435

Twitter

@XerisPharma

Next Earnings Date

2026-08-06

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	8.37	1.37B	314.85M	12.01M	47.52M	0.0655
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Aug-12-25	Resumed	H.C. Wainwright	Buy
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Jul 01, 2026

Insider 10b5-1 sales scheduled at XERS: 16,667 shares on 05/01 and 06/01/2026 - Stock Titan

Jul 01, 2026

Xeris Biopharma (NASDAQ: XERS) adds Nerissa Kreher and reshapes board - Stock Titan

Jun 30, 2026

Xeris CEO picks up chairman role at fast-growing biopharma - Crain's Chicago Business

Jun 30, 2026

Xeris Biopharma Holdings, Inc. Announces Board Changes, Effective July 1, 2026 - marketscreener.com

Jun 30, 2026

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity? - Insider Monkey

Jun 30, 2026

Xeris names CEO John Shannon as board chair, adds director - Investing.com

Jun 30, 2026

Xeris names CEO John Shannon as board chair, adds director By Investing.com - Investing.com Canada

Jun 30, 2026

Xeris Announces Updates to Its Board of Directors - Business Wire

Jun 30, 2026

Jun 26, 2026

Xeris Biopharma Holdings, Inc. Actuals & Estimates (NASDAQ:XERS) - TradingView

Jun 26, 2026